Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses

Molecular Therapy

Volumn 7, Issue 5, 2003, Pages 640-648

  Dileo, John ^a   Banerjee, Rajkumar ^a   Whitmore, Mark ^a,c   Nayak, Jayakar V ^b   Falo Jr , Louis D ^b   Huang, Leaf ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cervical cancer; E7; HPV; Liposome; LPD; Peptide vaccine

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; DNA; GLYCOPROTEIN P 15095; LIPID; LIPOSOME; PEPTIDE; PROTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; LYMPHOID TISSUE; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; VACCINE PRODUCTION;

ANIMALIA;

EID: 0038529616     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00064-9     Document Type: Article

References (40)

1. Gure, A. O., et al. (2000). Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc. Natl. Acad. Sci. USA 97: 4198-4203.
2. Real, F. X., et al. (1988). Class 1 (unique) tumor antigens of human melanoma: Identification of unique and common epitopes on a 90-kDa glycoprotein. Proc. Natl. Acad. Sci. USA 85: 3965-3969.
3. Real, F. X., Mattes, M. J., Houghton, A. N., Oettgen, H. F., Lloyd, K. O., and Old, L. J. (1984). Class 1 (unique) tumor antigens of human melanoma: Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J. Exp. Med. 160: 1219-1233.
4. Kao, H., et al. (2001). Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med. 194: 1313-1323.
5. van Driel, W. J., et al. (1999). Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial. Eur. J. Cancer 35: 946-952.
6. Houghton, A. N., Gold, J. S., and Blachere, N. E. (2001). Immunity against cancer: Lessons learned from melanoma. Curr. Opin. Immunol. 13: 134-140.
7. Dallal, R. M., and Lotze, M. T. (2000). The dendritic cell and human cancer vaccines. Curr. Opin. Immunol. 12: 583-588.
8. Babai, I., et al. (2001). A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine 20: 505-515.
9. Schuler, G., and Steinman, R. M. (1997). Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186: 1183-1187.
10. Karrer, U., et al. (1997). On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11-/-) mutant mice. J. Exp. Med. 185: 2157-2170.
11. Ochsenbein, A. F., et al. (1999). Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96: 2233-2238.
12. Zinkernagel, R. M., Ehl, S., Aichele, P., Oehen, S., Kundig, T., and Hengartner, H. (1997). Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity. Immunol. Rev. 156: 199-209.
13. Akbari, O., Panjwani, N., Garcia, S., Tascon, R., Lowrie, D., and Stockinger, B. (1999). DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189: 169-178.
14. Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K., and Falo, L. D. Jr (1996). DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2: 1122-1128.
15. + T cells after gene gun immunization. J. Exp. Med. 188: 1075-1082.
16. Maloy, K. J., et al. (2001). Intralymphatic immunization enhances DNA vaccination. Proc. Natl. Acad. Sci. USA 98: 3299-3303.
17. Lee, W. T., and Vitetta, E. S. (1991). The differential expression of homing and adhesion molecules on virgin and memory T cells in the mouse. Cell. Immunol. 132: 215-222.
18. Mackay, C. R. (1993). Homing of naive, memory and effector lymphocytes. Curr. Opin. Immunol 5: 423-427.
19. Mackay, C. R., Marston, W. L., and Dudler, L. (1990). Naive and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. 171: 801-817.
20. Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M., and Melief, C. J. (1996). Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156: 3911-3918.
21. Kyburz, D., Aichele, P., Speiser, D. E., Hengartner, H., Zinkernagel, R. M., and Pircher, H. (1993). T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23: 1956-1962.
22. Wang, R. F., and Wang, H. Y. (2002). Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20: 149-154.
23. Li, S., and Huang, L. (1997). In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4: 891-900.
24. Li, S., Rizzo, M. A., Bhattacharya, S., and Huang, L. (1998). Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 5: 930-937.
25. Whitmore, M., Li, S., and Huang, L. (1999). LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6: 1867-1875.
26. Whitmore, M. M., Li, S., Falo, L. Jr., and Huang, L. (2001). Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother. 50: 503-514.
27. Cheng, W. F., et al. (2001 ). Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108: 669-678.
28. Cheng, W. F., et al. (2001). Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 75: 2368-2376.
29. Ignatius, R., et al. (2000). Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood 96: 3505-3513.
30. Basak, S. K., et al. (2002). Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 99: 2869-2879.
31. McIlroy, D., et al. (2001). Investigation of human spleen dendritic cell phenotype and distribution reveals evidence of in vivo activation in a subset of organ donors. Blood 97: 3470-3477.
32. Moron, G., Rueda, P., Casal, I., and Leclerc, C. (2002). CD8alpha(2) CD11b(+) dencritic cells present exogenous virus-like particles to CD8(+) T cells and subsequently express CD8alpha and CD205 molecules. J. Exp. Med. 195: 1233-1245.
33. Ludewig, B., Barchiesi, F., Pericin, M., Zinkernagel, R. M., Hengartner, H., and Schwendener, R. A. (2000). In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 19: 23-32.
34. Tam, P., et al. (2000). Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther. 7: 1867-1874.
35. Li, B., et al. (2000). Lyophilization of cationic lipid-protamine-DNA (LPD) complexes. J. Pharm. Sci. 89: 355-364.
36. Terasawa, H., Tsang, K. Y., Gulley, J., Arlen, P., and Schlom, J. (2002). Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res. 8: 41-53.
37. Knutson, K. L., and Disis, M. L. (2001). Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin. Breast Cancer 2: 73-79.
38. Munger, K., et al. (2001). Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20: 7888-7898.
39. + T cells: New strategies for cancer vaccine design. J. Immunother. 24: 195-204.
40. Feltkamp, M. C., et al. (1993). Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23: 2242-2249.